首页 > 文章详情

2024年6月份FDA批准的抗肿瘤新药、新适应证一览

07月01日

整理：研值圈

来源：研值圈

2024年6月，美国FDA共批准了8个抗肿瘤药物，包括1个端粒酶抑制剂、1个RET抑制剂、1个ROS1/NTRK抑制剂、2个PD（L）1抑制剂、1个KRAS抑制剂和2个双抗，适应证涉及甲状腺癌、子宫内膜癌、结直肠癌、实体瘤、骨髓增生异常综合征、急性淋巴细胞白血病和淋巴瘤。其中，imetelstat是全球首款获批的端粒酶抑制剂。

参考文献

[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer
[3] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive
[4] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-chemotherapy-mismatch-repair-deficient-primary-advanced-or-recurrent
[5] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-chemotherapy-mismatch-repair-deficient-primary-advanced-or-recurrent
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell
[6] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-primary-advanced-or-recurrent-endometrial-carcinoma
[7] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer
[8] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma